Fairfield, Bush & Co’s Novo Nordisk NVO Stock Holding History

Fairfield, Bush & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$592K	Sell	16,096 -1,718	-10%	-$81.4K	0.33%	66
2025 Q4	$906K	Buy	17,814 +284	+2%	+$14.5K	0.48%	53
2025 Q3	$973K	Buy	17,530 +321	+2%	+$18.8K	0.5%	50
2025 Q2	$1.19M	Buy	17,209 +186	+1%	+$12.7K	0.67%	41
2025 Q1	$1.18M	Buy	17,023 +1,299	+8%	+$107K	0.75%	42
2024 Q4	$1.35M	Sell	15,724 -2,760	-15%	-$298K	0.8%	40
2024 Q3	$2.2M	Buy	18,484 +2,304	+14%	+$307K	1.31%	22
2024 Q2	$2.31M	Buy	16,180 +718	+5%	+$95.1K	1.38%	20
2024 Q1	$1.99M	Buy	15,462 +1,655	+12%	+$197K	1.18%	24
2023 Q4	$1.43M	Buy	13,807 +8,315	+151%	+$822K	0.84%	31
2023 Q3	$499K	Sell	5,492 -4,000	-42%	-$352K	0.33%	66
2023 Q2	$768K	Sell	9,492 -46,000	-83%	-$3.76M	0.21%	85
2023 Q1	$4.42M	Buy	55,492 +49,500	+826%	+$3.51M	1.56%	17
2022 Q4	$405K	Sell	5,992 -400	-6%	-$23.5K	0.27%	75
2022 Q3	$318K	Hold	6,392	–	–	0.22%	87
2022 Q2	$356K	Hold	6,392	–	–	0.21%	83
2022 Q1	$355K	Hold	6,392	–	–	0.18%	90
2021 Q4	$358K	Sell	6,392 -50,200	-89%	-$2.72M	0.17%	93
2021 Q3	$2.72M	Hold	56,592	–	–	0.88%	33
2021 Q2	$2.37M	Sell	56,592 -1,400	-2%	-$54.3K	0.64%	39
2021 Q1	$1.96M	Sell	57,992 -3,278	-5%	-$117K	0.56%	43
2020 Q4	$2.14M	Sell	61,270 -4,250	-6%	-$147K	0.62%	40
2020 Q3	$2.27M	Sell	65,520 -2,950	-4%	-$98.3K	0.73%	36
2020 Q2	$2.24M	Sell	68,470 -7,410	-10%	-$236K	0.8%	36
2020 Q1	$2.28M	Sell	75,880 -8,600	-10%	-$256K	0.95%	30
2019 Q4	$2.44M	Sell	84,480 -1,200	-1%	-$33.2K	0.9%	32
2019 Q3	$2.21M	Sell	85,680 -200	-0.2%	-$5.06K	0.77%	35
2019 Q2	$2.19M	Buy	85,880 +2,420	+3%	+$59.8K	0.75%	35
2019 Q1	$2.18M	Sell	83,460 -6,700	-7%	-$165K	0.72%	33
2018 Q4	$2.08M	Sell	90,160 -20	-0%	-$444	0.71%	36
2018 Q3	$2.13M	Sell	90,180 -1,200	-1%	-$29.3K	0.6%	40
2018 Q2	$2.11M	Sell	91,380 -11,540	-11%	-$274K	0.62%	39
2018 Q1	$2.53M	Sell	102,920 -12,650	-11%	-$332K	0.74%	32
2017 Q4	$3.1M	Buy	115,570 +6,450	+6%	+$164K	0.85%	32
2017 Q3	$2.63M	Buy	109,120 +8,130	+8%	+$184K	0.82%	32
2017 Q2	$2.17M	Sell	100,990 -400	-0.4%	-$8.07K	0.69%	36
2017 Q1	$1.74M	Sell	101,390 -200	-0.2%	-$3.48K	0.54%	43
2016 Q4	$1.82M	Buy	101,590 +9,570	+10%	+$173K	0.59%	42
2016 Q3	$1.91M	Buy	92,020 +1,200	+1%	+$29.8K	0.62%	39
2016 Q2	$2.44M	Buy	90,820 +5,820	+7%	+$160K	0.85%	35
2016 Q1	$2.3M	Sell	85,000 -5,140	-6%	-$138K	0.82%	37
2015 Q4	$2.62M	Buy	90,140 +30,750	+52%	+$851K	0.92%	36
2015 Q3	$1.61M	Sell	59,390 -47,900	-45%	-$1.36M	0.71%	42
2015 Q2	$2.94M	Buy	107,290 +4,660	+5%	+$131K	0.88%	39
2015 Q1	$2.74M	Buy	102,630 +1,430	+1%	+$32.9K	0.8%	42
2014 Q4	$2.14M	Buy	101,200 +12,060	+14%	+$269K	0.61%	45
2014 Q3	$2.12M	Sell	89,140 -800	-0.9%	-$18.4K	0.61%	46
2014 Q2	$2.08M	Buy	89,940 +68,150	+313%	+$1.5M	0.61%	46
2014 Q1	$497K	Sell	21,790 -3,450	-14%	-$73.5K	0.23%	65
2013 Q4	$93K	Sell	25,240 -67,400	-73%	-$1.17M	0.04%	112
2013 Q3	$1.57M	Sell	92,640 -9,550	-9%	-$161K	0.47%	55
2013 Q2	$1.58M	Buy	+102,190	New	+$1.7M	0.81%	31

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fairfield, Bush & Co's NVO Position: Q1 2026 in Review

Fairfield, Bush & Co reduced its Novo Nordisk (NVO) stake by 9.6% in Q1 2026, selling an estimated $81.4K and leaving 16,096 shares worth $592K. The position accounts for 0.33% of the portfolio, ranked #66.

Fairfield, Bush & Co first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.42M in Q1 2023. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Fairfield, Bush & Co held 16,096 shares of Novo Nordisk worth $592K as of Q1 2026.
Fairfield, Bush & Co sold 1,718 Novo Nordisk shares in Q1 2026, an estimated $81.4K.
Novo Nordisk made up 0.33% of Fairfield, Bush & Co's portfolio in Q1 2026, its #66 holding.
Fairfield, Bush & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
Fairfield, Bush & Co's Novo Nordisk position peaked at $4.42M in Q1 2023.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.